Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns

Hannan M. Braun, Jury Candelario, Courtney L. Hanlon, Eddy R. Segura, Jesse L. Clark, Judith S. Currier, Jordan E. Lake

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

36 Citas (Scopus)

Resumen

Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

Idioma originalInglés
Páginas (desde-hasta)371-375
Número de páginas5
PublicaciónLGBT Health
Volumen4
N.º5
DOI
EstadoPublicada - oct. 2017
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns'. En conjunto forman una huella única.

Citar esto